2024年1月9日 · Methods: A territory-wide retrospective study was conducted in Hong Kong to compare the efficacy of NMV-r and MOL against COVID-19 in unvaccinated adult patients with asthma, chronic obstructive pulmonary disease, bronchiectasis and interstitial lung diseases presenting with moderate COVID-19 from 16th February 2022 to 15th March 2023.

2024年1月9日 · We conducted a retrospective territory-wide cohort study in Hong Kong to investigate the efficacy of NMV-r and MOL among adult patients who had chronic respiratory diseases (COPD, asthma, bronchiectasis and interstitial lung diseases (ILD)), who were unvaccinated and hospitalized for COVID-19 with moderate severity at …

Methods: A territory-wide retrospective study was conducted in Hong Kong to compare the efficacy of NMV-r and MOL against COVID-19 in unvaccinated adult patients with asthma, chronic obstructive pulmonary disease, bronchiectasis and interstitial lung diseases presenting with moderate COVID-19 from 16th February 2022 to 15th March 2023.

The efficacy of nirmatrelvir plus ritonavir (NMV-r) for vaccinated COVID-19 patients at high risk of progression is not adequately recognised. To address this gap, we conducted a systematic review and meta-analysis of current literature.

2024年4月29日 · This randomized, double-blind, placebo-controlled, multinational trial showed that NMV/r reduced the risk of COVID-19–related hospitalization or death from any cause by 86% when patients were treated within 5 days of symptom onset (0.9% vs. 6.5%, absolute risk in treated vs. placebo, respectively; P < 0.001). 8 In contrast to EPIC-HR, which ...

2023年7月7日 · In our study, we aimed to investigate the efficacy of 3RDV vs. NMV/r in preventing hospitalization among mainly immunocompromised, vaccinated, high-risk outpatients with COVID-19, during the predominance of the Omicron variant, by using inverse probability of treatment weighting (IPTW) techniques to account for inherent bias when choosing ...

2025年2月20日 · Nirmatrelvir/ritonavir (PaxlovidTM) (NMV/r) was the first oral therapeutic agent available for outpatient treatment of mild-to-moderate COVID-19, reducing morbidity and mortality.

2024年1月9日 · Methods A territory-wide retrospective study was conducted in Hong Kong to compare the efficacy of NMV-r and MOL against COVID-19 in unvaccinated adult patients with asthma, chronic obstructive...

2023年2月23日 · In Hong Kong, MOV and NMV-r prescriptions in high-risk patients with mild-to-moderate COVID-19 were also associated with significant cost savings [7]. In another real-world study conducted in Hong Kong, the use of NMV-r but not MOV was associated with a reduced risk of hospitalization in non-hospitalized COVID-19 patients [8].

2024年6月6日 · In randomized controlled trials, Nirmatrelvir/ritonavir (NMV/r) and Molnupiravir (MPV) reduced the risk of severe/fatal COVID-19 disease. Real-world data are limited, particularly studies directly comparing the two agents.